Hyperuricemia Resistant to a Xanthine Oxidase Inhibitor, Topiroxostat: a Case Report

被引：0
|
作者：
Takahide Kimura
Seiki Yamada
Masayuki Tanemoto
机构：
[1] International University of Health and Welfare,Division of Nephrology, Department of Internal Medicine
来源：
SN Comprehensive Clinical Medicine | / 4卷 / 1期
关键词：
Chronic kidney disease; Gout; Hyperuricemia; Xanthine oxidase;
D O I：
10.1007/s42399-021-01081-1
中图分类号：
学科分类号：
摘要：
Hyperuricemia is a common complication of chronic kidney disease. Gout is a clinical symptom of hyperuricemia, and lowering serum uric acid concentration (sUA) is recommended to prevent its recurrence. Febuxostat and topiroxostat are sUA-lowering agents, which are presumed to act on the same site of xanthine oxidase (XO), the rate-limiting enzyme for urate production. We present a case of gout where febuxostat but not topiroxostat lowered sUA. The different efficacy between them indicates that XO inhibitors are not interchangeable even among those acting on the same site of XO.
引用
收藏
相关论文
共 50 条
  • [21] Lesinurad, a Selective URAT-1 Inhibitor With a Novel Mechanism in Combination With a Xanthine Oxidase Inhibitor, for Hyperuricemia Associated With Gout
    Huneycutt, Emily
    Board, Chase
    Clements, Jennifer N.
    JOURNAL OF PHARMACY PRACTICE, 2018, 31 (06) : 670 - 677
  • [22] QT/QTc Study Conducted in Japanese Adult Healthy Subjects: A Novel Xanthine Oxidase Inhibitor Topiroxostat Was Not Associated With QT Prolongation
    Sugiyama, Atsushi
    Hashimoto, Hiroya
    Nakamura, Yuji
    Fujita, Tomoe
    Kumagai, Yuji
    JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (04): : 446 - 452
  • [23] The role of xanthine oxidase in thiopurine metabolism: A case report
    Wong, Dennis R.
    Derijks, Luc J. J.
    den Dulk, Meyno O.
    Genuneke, Edy H. K. M.
    Hooymans, Piet M.
    THERAPEUTIC DRUG MONITORING, 2007, 29 (06) : 845 - 848
  • [24] Uric-Acid Lowering Treatment by a Xanthine Oxidase Inhibitor Improved the Diastolic Function in Patients with Hyperuricemia
    Ogino, Kazuhide
    Kinugasa, Yoshiharu
    Kato, Masahiko
    Yamamoto, Kazuhiro
    Hamada, Toshihiro
    Hisatome, Ichiro
    JOURNAL OF CARDIAC FAILURE, 2019, 25 (08) : S26 - S26
  • [25] Effect of the Xanthine Oxidase Inhibitor, Febuxostat, on WBC Count in Asymptomatic Hyperuricemia: Subanalysis of the Randomized PRIZE Study
    Takeshita, Mitsuhide
    Tanaka, Atsushi
    Yoshida, Hisako
    Nakamura, Ikuko
    Shibata, Yoshisato
    Hata, Shiro
    Kushiyama, Akifumi
    Okutsu, Masaaki
    Ishizu, Tomoko
    Node, Koichi
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2024, 31 (06) : 864 - 875
  • [26] Xanthine Oxidase and NADPH Oxidase Induce Cardiovascular Endothelial Dysfunction During Hyperuricemia
    Zhang, Suhua
    Huang, Harer
    Serpillon, Sabrina
    Wang, Ziping
    Yu, Xiaohan
    Hintze, Thomas H.
    FASEB JOURNAL, 2008, 22
  • [27] Influence of xanthine oxidoreductase inhibitor, topiroxostat, on body weight of diabetic obese mice
    Nakamura, Takashi
    Nampei, Mai
    Murase, Takayo
    Satoh, Etsuko
    Akari, Seigo
    Katoh, Noriaki
    Mizukami, Hiroki
    NUTRITION & DIABETES, 2021, 11 (01)
  • [28] Influence of xanthine oxidoreductase inhibitor, topiroxostat, on body weight of diabetic obese mice
    Takashi Nakamura
    Mai Nampei
    Takayo Murase
    Etsuko Satoh
    Seigo Akari
    Noriaki Katoh
    Hiroki Mizukami
    Nutrition & Diabetes, 11
  • [29] Endothelial dysfunction and hyperuricemia:: role of xanthine-oxidase enzyme
    Jiménez, RT
    Puig, JG
    REVISTA CLINICA ESPANOLA, 2002, 202 (10): : 549 - 551
  • [30] RENAL PROTECTIVE EFFECTS OF TOPIROXOSTAT AND FEBUXISTAT, NEWLY AVAILABLE XANTHINE OXIDASE INHIBITORS: IN THE HYPERTENSIVE PATIENTS
    Satoh, F.
    Tezuka, Y.
    Omata, K.
    Ono, Y.
    Shiratori, B.
    Kudo, M.
    Morimoto, R.
    Ito, S.
    JOURNAL OF HYPERTENSION, 2019, 37 : E263 - E263
12345